Sweden Fidelio Capital Sturegatan 10 114 36 Stockholm
United Kingdom Fidelio Capital 14-16 Bruton Place London W1J 6LX
Revenue growth
Increase in # employees
Companies added
Having successfully created AniCura in 2011, today part of Mars Petcare and representing one of the largest pet care and pet clinic chains in Europe, Fidelio decided to leverage its gained insights into the broader animal health industry. The journey started with investments in innovation-driven and entrepreneurial businesses within attractive sub-segments of animal health, with the ambition to combine these and establish global category leaders. At the time, many of these sub-segments were highly fragmented and served mainly by smaller, entrepreneurial businesses with limited capabilities to scale. On the other hand, they were also characterised by relatively high entry barriers and strong profitability, supported by scalable business models and IP/patent protection.
Vimian’s story begins in 2015 with Fidelio acquiring a provider of pet allergy diagnostics and treatment. Since then, Fidelio has, in collaboration with strong entrepreneurs and management teams, targeted the companion and production animal health market, continuing to build what is today known as Vimian. The group now operates in four fast-growing animal health verticals: Specialty Pharma, MedTech, Veterinary Services and Diagnostics.
Following the successful listing of Vimian on the Stockholm Stock Exchange in June 2021, with Fidelio retaining its role as an active majority owner, Vimian has continued to grow through an ambitious strategy across all businesses and verticals.
Since inception, Vimian has partnered with numerous companies globally.
Today, Vimian sells its products and services to countries across the world.
Combine the strengths and capabilities of a global Group with the intimacy, speed, and creativity of an owner-led business.
Vimian is a global animal health company with a passion for making a positive impact through offering animals the best available care. The Group puts science, technology and its customers’ needs at the centre, aiming to deliver effective solutions to animals and veterinary professionals around the world.
During the period between 2015-2018, Fidelio acquired Nextmune, Indical, VetFamily and Movora - four prominent companies within the animal health market, each specialising in their respective niche markets, namely Speciality Pharma, Diagnostics, Veterinary Services and MedTech. In 2021, recognising an attractive opportunity to accelerate continued organic growth as well as to improve collaborative efforts, Fidelio made the strategic decision to gather all four businesses under a shared umbrella, with the foundation of Vimian – a global group of leading niche animal health companies.
In June 2021, Vimian was listed on the Stockholm Stock Exchange, with Fidelio maintaining its role as an active and supportive majority owner.
Company info
CEO
Patrik Ericsson
Head Office
Stockholm, Sweden
Employees
1,100
Acquisition year
2015
Industry
Animal health
Website
vimian.com
